Mechanism · Research Data · Side Effects · No Doses
Somatropin is lab-made human growth hormone, and it is a real, approved medicine, but only for specific diagnosed conditions like childhood growth hormone deficiency, Turner syndrome and adult GH deficiency. Using it for anti-ageing or bodybuilding is a completely different, off-label story with far thinner evidence and is not approved anywhere. The famous 1990 study people quote for anti-ageing was a small trial in deficient older men, not proof it works for healthy adults. This page keeps the approved-medicine research and the off-label claims clearly separated, and it does not publish doses.
| Evidence Type | Status |
|---|---|
| Human RCT | ✔ (extensive, for approved indications) |
| Observational | ✔ |
| Animal Studies | ✔ |
| In Vitro | ✔ |
| Regulatory Approval | ✔ for specific medical indications (EMA/HPRA-approved products); ✗ for anti-ageing, cosmetic or bodybuilding/performance use (not an approved indication in any jurisdiction) |
The largest and most robust body of somatropin clinical trial literature covers paediatric use for growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, chronic kidney disease-related growth failure and small-for-gestational-age children. Decades of RCT data demonstrate improved height velocity and adult height outcomes with appropriately dosed and monitored treatment.
Clinical trials in adults with confirmed GH deficiency (often due to pituitary disease, surgery or radiotherapy) have examined body composition, bone density, lipid profile, exercise capacity and quality-of-life outcomes with somatropin replacement, generally reporting improvements in lean mass, reductions in fat mass, and improved quality-of-life measures compared to placebo.
A body of research, including the widely cited Rudman et al. 1990 study, has examined GH administration in healthy or age-related GH-declining older adults, reporting changes in body composition (increased lean mass, decreased fat mass) and skin thickness. However, this research does not constitute regulatory approval for anti-ageing use, and subsequent reviews and regulatory bodies have consistently emphasised that GH is not approved for this purpose in any jurisdiction, citing an unfavourable risk-benefit ratio in individuals without a diagnosed GH deficiency.
GH is used off-label in bodybuilding and performance-enhancement contexts for its anabolic and body-composition effects. This use is not supported by controlled trials in healthy, non-deficient athletic populations of the scale seen for approved indications, is not an approved use anywhere, and GH is prohibited by the World Anti-Doping Agency (WADA) at all times.
| Study / Model | Reported Effect |
|---|---|
| Paediatric GHD RCTs (multiple, decades of data) | Consistent, well-documented improvement in height velocity and near-adult height outcomes with appropriately monitored somatropin therapy versus untreated GHD. |
| Adult GHD replacement RCTs | Improved lean body mass, reduced fat mass, improved bone mineral density and quality-of-life scores versus placebo in confirmed AGHD populations. |
| Rudman DR et al. 1990 (healthy older men study) | Reported increased lean body mass and decreased adipose tissue mass, and increased skin thickness, in men aged 61-81 with low baseline IGF-1; frequently cited (and frequently over-extrapolated) in anti-ageing marketing contexts. |
| Turner syndrome growth trials | Demonstrated improved final adult height outcomes with somatropin treatment versus untreated historical controls. |
| Athletic performance RCTs in healthy, non-GHD adults | Evidence for meaningful athletic performance enhancement in healthy, non-deficient adults is notably weaker and more mixed than body-composition findings; several systematic reviews report limited effect on strength/power output despite body-composition changes. |
The side-effect profile is comparatively well characterised for approved, appropriately dosed and monitored clinical use. Off-label use at supraphysiological doses outside medical supervision carries materially different and less well-quantified risks, particularly around glucose metabolism, cardiac structure and long-term proliferative signalling.
Sport status: Growth hormone, including somatropin, is prohibited at all times under S2.2.3. See the WADA 2026 Prohibited List.
Is HGH (Somatropin) a legal, approved medicine?
Yes, for specific diagnosed conditions. Somatropin is an EMA- and HPRA-approved prescription medicine in Ireland for indications including paediatric growth hormone deficiency, Turner syndrome, Prader-Willi syndrome and adult growth hormone deficiency, and it requires a valid prescription and medical supervision.
Is HGH approved for anti-ageing or bodybuilding use?
No. Anti-ageing and bodybuilding or performance use is off-label and is not an approved indication in Ireland, the EU or anywhere else. This use is not supported by the same scale of controlled trial evidence as the approved indications, and the World Anti-Doping Agency prohibits GH at all times.
What did the famous 1990 Rudman study on HGH actually find?
Rudman et al. (1990, New England Journal of Medicine) studied GH administration in men aged 61 to 81 with low baseline IGF-1, reporting increased lean body mass, decreased fat mass and increased skin thickness. It is frequently cited in anti-ageing marketing, but it was a small study in a specific deficient population, not evidence for GH use in healthy adults.
What are the main documented risks of Somatropin?
In approved, monitored clinical use, documented effects include fluid retention, joint pain, carpal tunnel syndrome and reduced insulin sensitivity. At the supraphysiological doses seen in off-label misuse, research including the SAGhE study flags additional and less well-quantified risks, including acromegaly-like changes and ongoing monitoring for proliferative signalling concerns.
More evidence-based peptide research guides, free.
Browse the Research GuidesTracking food too? Calorie counter with barcode scanner →
